Setting new standards in information exchange for the pharmaceutical and biotech industry
New Targeted Immunotherapy Combination for Advanced Melanoma Approved by FDA
June 28, 2018
The FDA approved on Wednesday, Array Biopharma Inc’s oral IO combination treatment of Braftovi (encorafenib) plus Mektovi (binimetinib) for patients with advanced melanoma that have BRAF V600E or V600K gene mutations.
“The progression-free survival (PFS) and overall survival (OS) advantages seen to date with the combination compared with monotherapy are ‘unprecedented’ in the field of targeted therapy for melanoma,” said Jeffrey Weber, MD, PhD, NYU Langone Medical Center and Immuno-Oncology 360° 2018 Keynote in a recent interview.
Array Biopharma released data earlier this year that showed the combination led to a median OS of 33.6 months in comparison to a median OS of 16.9 months in patients in the controlled arm of the study that were given Roche’s, Zelboraf.
The small biotech’s combination drugs will be up against Roche’s combination of Zelboraf and Cotellic and Novartis’ combination of Tafinlar and Mekinist in the market. These organizations represent just a few of the already approved combination therapies across several cancer types.
Novartis will be presenting at Rational Combinations 360° on investment strategies driving IO combinations taking place in September in Philadelphia.
The 3rd annual Rational Combinations 360° program delves into the emerging clinical data, the science driving immunotherapy combinations and business aspects in combination strategies that fight a wider range of cancers.
Read the full article here.
Learn more about Rational Combinations 360° here.